The outbreak of COVID-19 posed a huge threat to human health and social stability. With the rapid spread of the virus around the world, the drug development and related research of novel coronavirus (SARS-CoV-2) have become an urgent issue in the medical field. COVID-19 fails into the category of epidemics in the theory of TCM. LHQW capsule has repeatedly played an important role in many major epidemics. Previous studies have shown that LHQW capsule can inhibit the biological activity of varied viruses including MERS-CoV and SARS-CoV. The paper summarizes the relevant research data and achievements of LHQW capsule in the past few years, reviews the chemical constituents, clinical efficacy and pharmacological effects of LHQW capsule, and provides scientific basis for the anti-virus mechanism of LHQW capsule and clinical treatment of COVID-19. (English) [ABSTRACT FROM AUTHOR] 新型冠状病毒肺炎（COVID-19）疫情的爆发对人类健康与社会稳定造成了巨大威胁。随着病毒在全球迅速蔓 延，针对新型冠状病毒（SARS-CoV-2）的药物开发及其相关研究成为医学领域的迫切问题。COVID-19 归入中医学理论中的 疫病范畴，连花清瘟胶囊（颗粒）屡次在重大疫情中发挥重要作用。既往研究表明，连花清瘟胶囊可能抑制 MERS-CoV、 SARS-CoV 等多种病毒的生物活性。该文整理了历年国内外有关连花清瘟胶囊相关研究成果，从其化学成分、临床功效以 及药理作用等方面进行综述分析，以期对连花清瘟胶囊抗病毒机制研究和新冠肺炎临床治疗提供科学依据。 (Chinese) [ABSTRACT FROM AUTHOR] Copyright of Journal of Pharmaceutical Practice is the property of Journal of Pharmaceutical Practice Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Research progress on chemical composition and clinical efficacy of Lianhua Qingwen (LHQW) capsule, a traditional Chinese medicine (TCM) used to treat COVID-19